We have located links that may give you full text access.
A seamless phase II/III design with sample-size re-estimation.
Journal of Biopharmaceutical Statistics 2009 July
A main objective in clinical trials is to find the best treatment in a given finite class of competing treatments and then to show superiority of this treatment against a control treatment. Traditionally, the best treatment is estimated in a phase II trial. Then in an independent phase III trial, superiority of this treatment, estimated as best in the first trial, is to be shown against the control treatment by a size alpha test. In this paper we investigate a competing adaptive two-stage test procedure for a seamless phase II/III trial. We assume that the variance is unknown and include therefore the calculation of the total sample size based on the first-stage-variance estimation. We derive formulae for the expected number of patients. These formulae depend on the unknown variance only, not on the other unknown parameters. Using a prior for the unknown variance, we can determine the two-stage test procedure of size alpha and power 1 - beta that is optimal in that it needs a minimal number of observations. The results are illustrated by a numerical example that indicates the superiority of the adaptive procedure over the traditional approach.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app